Medexus Pharmaceuticals Inc (MDP) AI Stock Analysis

• Market Cap: C$86.45M
• Dividend Yield: N/A
• Average Volume (3M): 46.68K
• Price to Earnings (P/E): 64.5
• Beta (1Y): 1.32
• Revenue Growth: 2.14%
• EPS Growth: -83.06%
• Country: CA
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 32,258,354
• 10 Day Avg. Volume: 30,861
• 30 Day Avg. Volume: 46,683
• PEG Ratio: -0.02
• Price to Book (P/B): 0.83
• Price to Sales (P/S): 0.40
• P/FCF Ratio: 2.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$6.00
• Price Target Upside: 122.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: C$3.00 ▲(11.11% Upside)

Medexus Pharmaceuticals Inc's overall stock score reflects a mixed financial performance with stable gross margins but declining revenue and cash flow. The technical analysis indicates bearish trends, while the high P/E ratio suggests overvaluation. The earnings call provided some optimism with successful product launches and cost reductions, but challenges remain with declining revenue and competitive pressures.

Positive Factors

Successful Product Launch

The successful launch of GRAFAPEX, with strong patient demand and positive cash flow contributions, indicates robust market acceptance and potential for sustained revenue growth.

Cost Reduction Initiatives

The significant reduction in manufacturing costs for IXINITY enhances margin sustainability and operational efficiency, strengthening the company's competitive position.

Positive Reimbursement Developments

Improved reimbursement for GRAFAPEX under the NTAP program facilitates adoption, boosting long-term revenue potential and market penetration.

Negative Factors

Revenue Decline

The decline in net revenue suggests challenges in maintaining sales growth, which could impact future earnings and market share if not addressed.

Generic Competition Impact

The significant drop in demand for Rupall due to generic competition highlights vulnerability in product lines, affecting revenue stability.

Decreased Demand for Key Products

Falling demand for Rasuvo and Metoject indicates competitive pressures and market challenges, potentially reducing future revenue streams.

Medexus Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Medexus Pharmaceuticals Inc. (MDP) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions for patients with rare diseases and unmet medical needs. Operating primarily in the pharmaceutical sector, Medexus specializes in a range of products, including hematology and autoimmune therapies, with a commitment to enhancing patient outcomes through effective treatments. The company is dedicated to expanding its portfolio through strategic partnerships and collaborations, as well as leveraging its expertise in drug development and commercialization.

How the Company Makes Money

Medexus Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, which include proprietary and licensed treatments for various conditions. The company has established key revenue streams through direct sales to healthcare providers and partnerships with other pharmaceutical companies for product distribution and co-marketing agreements. Additionally, Medexus benefits from government and private insurance reimbursements for its medications, which further contributes to its earnings. Significant partnerships with healthcare organizations and ongoing investment in research and development also play a crucial role in driving the company's revenue growth, as they enable Medexus to expand its portfolio and reach new markets.

Medexus Pharmaceuticals Inc Financial Statement Overview

Summary

Medexus Pharmaceuticals Inc shows a mixed financial performance. The company has a stable gross profit margin and improved leverage, but faces challenges with negative revenue growth and declining cash flow. Profitability and cash flow enhancement are needed to strengthen its financial position.

Income Statement

Medexus Pharmaceuticals Inc shows a mixed performance in its income statement. The company has maintained a stable gross profit margin around 52%, indicating efficient production and pricing strategies. However, the net profit margin is low at 2.07% TTM, reflecting limited profitability. Revenue growth has been negative recently, with a decline of 2.46% TTM, which could be a concern for future earnings potential. The EBIT and EBITDA margins are moderate, suggesting operational efficiency but room for improvement.

Balance Sheet

The balance sheet reveals a moderate financial position. The debt-to-equity ratio has improved to 0.71 TTM from higher levels in previous years, indicating better leverage management. However, the return on equity is modest at 5.97% TTM, suggesting limited returns for shareholders. The equity ratio is not explicitly calculated, but the company's equity position has strengthened over time, which is a positive sign.

Cash Flow

Cash flow analysis shows some challenges. The free cash flow growth rate is negative at -20.50% TTM, indicating a decline in cash generation. However, the operating cash flow to net income ratio is healthy at 0.25, suggesting good cash conversion. The free cash flow to net income ratio is high at 0.89, indicating efficient cash utilization despite the decline in free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	105.66M	108.33M	113.05M	108.10M	76.70M	79.66M
Gross Profit	55.52M	56.58M	59.51M	60.04M	37.93M	42.01M
EBITDA	15.92M	16.81M	19.28M	16.14M	15.16M	-23.61M
Net Income	806.00K	2.25M	-214.00K	1.22M	-2.88M	-28.26M
Balance Sheet
Total Assets	153.79M	171.84M	155.73M	161.33M	139.22M	148.51M
Cash, Cash Equivalents and Short-Term Investments	9.33M	23.97M	5.25M	13.07M	10.02M	18.70M
Total Debt	21.89M	37.18M	49.90M	94.72M	54.86M	56.40M
Total Liabilities	100.83M	119.69M	125.41M	187.70M	151.82M	130.50M
Stockholders Equity	52.96M	52.14M	30.32M	22.45M	17.79M	18.02M
Cash Flow
Free Cash Flow	16.94M	21.31M	18.45M	-1.81M	-8.89M	-5.72M
Operating Cash Flow	19.76M	24.03M	18.71M	-1.44M	-1.18M	5.04M
Investing Cash Flow	-7.87M	-6.00M	-3.48M	-1.72M	-8.20M	-11.70M
Financing Cash Flow	-11.00M	796.00K	-23.05M	6.41M	663.00K	18.68M

Medexus Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Negative. The current price of 2.7 is below the 20-day moving average (MA) of 2.73, below the 50-day MA of 2.80, and below the 200-day MA of 2.80, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 46.99 is Neutral, neither overbought nor oversold. The STOCH value of 38.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MDP.

Medexus Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	76 Outperform	C$126.23M	15.12	22.35%	1.81%	22.22%	25.50%
OGI	59 Neutral	C$283.43M	70.33	1.86%	―	38.86%	―
MDP	57 Neutral	C$86.45M	64.48	0.87%	―	2.14%	-83.06%
MPH	52 Neutral	C$13.57M	-3.96	-18.39%	―	24.30%	-68.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AQS	21 Underperform	C$663.17K	-0.81	―	―	192.96%	42.59%

Medexus Pharmaceuticals Inc Corporate Events

Medexus Pharmaceuticals Reports Strong GRAFAPEX Performance Amidst Revenue Challenges

Medexus Pharmaceuticals reported its fiscal Q2 2026 results, highlighting the strong performance of its product GRAFAPEX, which has exceeded expectations since its launch. Despite a decrease in overall net revenue due to competition and the termination of a previous agreement, GRAFAPEX’s success has positively impacted the company’s financials, with significant engagement from US transplant centers and expectations of accretive cash flows by Q4 2025. This positions Medexus well for future growth, despite challenges from generic competition affecting other products.

The most recent analyst rating on (TSE:MDP) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals to Discuss Q2 2026 Financial Results

Medexus Pharmaceuticals has announced a conference call scheduled for November 13, 2025, to discuss its second fiscal quarter results ending September 30, 2025. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market position and investor confidence.

The most recent analyst rating on (TSE:MDP) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals Announces Election of Directors and Auditor Appointment

Medexus Pharmaceuticals held its virtual annual meeting of shareholders, where all director nominees were elected, and PricewaterhouseCoopers LLP was appointed as the company’s auditors. The approval of these proposals reflects strong shareholder support, potentially reinforcing Medexus’s strategic direction and stability in the pharmaceutical industry.

The most recent analyst rating on (TSE:MDP) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals Earnings Call: Cautious Optimism Amid Challenges

The recent earnings call for Medexus Pharmaceuticals was characterized by cautious optimism. The company highlighted several strategic achievements, including the successful launch of GRAFAPEX and improved gross margins. However, these positives were tempered by challenges such as declining revenues and adjusted EBITDA, increased expenses, and concerns about tariffs affecting costs. The overall sentiment was one of cautious optimism, with a focus on future growth driven by GRAFAPEX.